Welcome to Dragonfly Biosciences, Europe’s leading premium retailer of Cannabidiol (CBD).

A research-fuelled and community-minded company, Dragonfly controls the process from seed to sale, guaranteeing the highest and most consistent product quality. We work strictly within the frontiers of current legislation and operate with total transparency, keeping our fields, processing facility, laboratories and products open to consumers.

Currently offering a range of CBD health and lifestyle products, Dragonfly aims to expand its business and product range in line with legal changes in Europe.

As demand grows for CBD health supplements, we will continue to be the go-to producer and supplier of Cannabidiol for both businesses and consumers.

Why Choose Us?


Why Choose Us?


Guaranteed accurate concentration (%) of CBD


Produced under stringent control and tested by independent, accredited labs


Organically certified product


Customer service that can help you before, during and after the purchase

All our products are tested in third-party laboratories, as well as our own to ensure consistency and quality across the board. Dragonfly works under Good Manufacturing Practices (GMP). Our product line is standardised to contain specific quantities of cannabinoids including, CBD, CBD-a and CBG. We guarantee that our products are 100% organic. Click here to read more…

Our Team
The Team


The Team


President & Co-Founder

Radost is an entrepreneur and experienced businesswoman, based in Sofia.

Equipped with a law degree, she spent her early years as head of the Legal Department at Sofia Municipality, responsible for all large-scale urban development, architecture, and infrastructure-focused projects.

Radost has developed a series of solar farms, a successful TV production company and now is dedicated to building Dragonfly Biosciences.


Executive Chairman

Chris is a serial entrepreneur and investor. With experience in both media and health-related industries.

Chris is acting CEO; having previously been involved in Wellbeing Network, where he also served as a CEO.

In 1991, Chris founded Chello Zone Holdings (also known as Zone Vision Networks) an England-based TV company. Chris served as President; he developed and expanded Zone Vision Networks worldwide.

Chello Zone was sold to Liberty Global and then in 2014 sold to AMC Networks as part of the Chellomedia sale for more than $1.0bn

Chris also ran Sapphire Media, which was sold to (LFP) Larry Flynt Productions and Zone Studios which was sold to BTI.


Co-Founder & Board Member

Mark has over 30 years experience in the media industry; film, television and music.

Initially a kidnap and ransom broker at Lloyds of London, he then became one of the original team members of Henson International Television, the creators of The Muppet Show.

After several productions in TV, music and film, he put together a group that raised US$250m to acquire the International Library Rights to titles in and the Hallmark Channel.  This was subsequently acquired by NBCUniversal in 2007.

Subsequently, Mark has multiple investments in digital media.


Chief Executive Officer

Regan is a Chartered Accountant with over 20 years of experience in the media industry.

Regan has spent 4 years at NBCUniversal where he served as VP Finance in the Emerging Markets and International Corporate divisions.

Previously, Regan spent 8 years at Chello Zone where he served as CFO supporting the worldwide expansion and the eventual sale of Chellomedia to AMC Networks.

Prior to that, Regan spent 8 years at the BBC where he held various senior finance roles.

Regan qualified with Moore Stephens in 1994


Advisory Board Member

Dermot is a chartered accountant and global executive with over 20 years’ experience leading complex, high-growth, multi-national organizations. He has been Chief Executive Officer of Zone Vision Networks Ltd. since January 2002 and played a key role in building and selling the (US$ 1 billion) company. Fabled for his operational control, commercial creativity and strategic planning, Dermott has helped to grow brands such as CNBC, Discovery, Animal Planet, Food Network, CBS, Extreme Sports, Outdoor Channel, MGM and AMC.



Advisory Board Member

Saoirse brings 15 years of cannabinoid wisdom to the Dragonfly board. Previously serving as Associate Professor at the University of Nottingham, her research is centred in on the endocannabinoid system, with a particular focus on the role it plays in diabetes and obesity. Since 2016, she has been named Young Investigator of the Year by the International Cannabinoid Research Society and acted as a source of expertise for numerous BBC documentaries. A seasoned academic, she will keep us at the cutting edge of new research findings.


Advisory Board Member

Andy is a pharmacist armed with a PhD in cannabinoid medical chemistry from the University of Nottingham, his own pharmaceutical consultancy and over 15 years’ experience in the industry. He is also the pharmacy lead for the Centre for Medicinal Cannabis and has a wealth of experience in the realms of academia, biotechnology and peer pharma. Andy will keep Dragonfly updated with the latest cannabinoid research insights, including new theories, papers and data.


Investor & Board Member

Paul has more than 25 years leadership experience in the pharmaceutical industry. After spending 14 years at GlaxoSmithKline (GSK), including a stint as the General Manager of Europe, Paul later became the Executive Vice President of Worldwide Commercial Operations at Gilead Sciences Inc. He also spent four years working at Arthur Anderson and is now the board director of several biotech companies, as well as being a Fellow of the UK Chartered Institute of Management Accountants.

Our Team

What is CBD?

Cannabidiol, or CBD, is just one of the 113 cannabinoids naturally found in the Cannabis sativa plant. In contrast to the more commonly known cannabinoid, THC, it has no psychoactive properties, is completely legal, and when isolated, can have a multitude of health benefits.

More information here 

Extraction Process

After harvesting, our three stage state of the art extraction process is used to produce the highest quality CBD. We use an ethanol method as it both maximises product flexibility and better suits the scale of our operation.

Oil extraction and other product development is undertaken by industry experts in the Pharmaceutical division of Dragonfly. All our products are then processed and packaged in a GMP certified facility.


Our Product Range

We work with independent labs across the country to test our PCR hemp oil. Accurately testing the product is of utmost importance to ensure our customers the highest quality of our product. No harmful solvents are used in the processing of our products.


In association with

In association with

The Harley Building, 77-79 New Cavendish Street
London W1W 6XB, United Kingdom

You can also email us at [email protected] or call us on +44 20 7111 0807 (Mon-Fri 9:30am to 5:30pm, excluding UK bank holidays).
To contact the Dragonfly Biosciences Press Office please email [email protected]
For high-quality bulk, white label and wholesale solutions; powered by vertical integration, get in touch with Dragonfly Wholesale.